Daniel Wei Lin MD

Surgical Oncology

Professor of Urology, University of Washington

1660 S Columbian WaySection of Urology 112guSeattle, WA 98108
Phone+1 206-764-2265
Fax+1 206-764-2239

Dr. Lin is on Doximity

As a Doximity member, you’ll join more than three million U.S. healthcare professionals—including 85+% of physicians, and 2/3 of all NPs and PAs—in a private, secure network.

Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
Connect with colleagues in the same hospital or clinic.
Read the latest clinical news, personalized to your specialty.

See Dr. Lin's full profile Already have an account?

Summary

Dr. Daniel Lin is a Urologist based in Seattle, WA, with a subspecialty in Urologic Oncology. He is currently Professor and Interim Chair of Urology, holding the Pritt Family Endowed Chair in Prostate Cancer Research and is the Director of the Institute for Prostate Cancer Research. He underwent his fellowship in Urologic Surgical Oncology at Memorial Sloan Kettering Cancer Center post his residency in Urology at the University of Washington. Dr. Lin currently holds positions at multiple institutions including the Fred Hutchinson Cancer Center, University of Washington School of Medicine, Children’s Hospital and Regional Medical Center, among others. His expertise lies in urologic oncology and robotic prostatectomy and also has multiple publications in various well-established journals. He has participated in several clinical trials and has been the recipient of multiple awards including being listed in America's Top Doctors by Castle Connolly.

Education & Training

Memorial Sloan Kettering Cancer CenterFellowship, Urologic Surgical Oncology, 2000 - 2001
University of Washington School of Medicine1998 - 2000
University of WashingtonResidency, Urology, 1994 - 2000
University of Washington School of Medicine1996 - 1998
University of WashingtonInternship, Surgery, 1994 - 1995

The following disclaimer is related to board certifications obtained from ABMS®, denoted by the ABMS® logo.

This information is proprietary data maintained in a copyrighted database owned by the American Board of Medical Specialties®. The display and presence of ABMS Data in no way constitutes any affiliation, association with, or endorsement of any advertising, promotion, or sponsorship by ABMS and its affiliates and subsidiaries, the ABMS Member Boards, or ABMS board certified physicians and medical specialists. Copyright 2026 American Board of Medical Specialties®. All rights reserved.

The user is responsible for ensuring that the profile obtained in this directory is the profile of the physician or medical specialist being sought.

A self-designated specialty, subspecialty, or practice area neither implies nor is equivalent to ABMS board certification or the existence of specialized training by or competence of a physician or medical specialist.

Certifications & Licensure

MT State Medical License 2022 - 2028
AK State Medical License 2022 - 2026
WA State Medical License 1997 - 2026
NY State Medical License 2000 - 2002
American Board of Urology Urology

Awards, Honors, & Recognition

America's Top Doctors Castle Connolly, 2012-2014
America's Top Doctors for Cancer Castle Connolly, 2011-2013
AUA Leadership Program American Urological Association, 2010

Clinical Trials

Effects of ASA on Prostate Tissue
COMPLETED
NA
Prostate Active Surveillance Study
RECRUITING
Effects of Sulforaphane on Normal Prostate Tissue
COMPLETED
PHASE1, PHASE2

Publications & Presentations

PubMed

The clinical utility of prostate MRI before biopsy.
Connor Chestnut, Trevor McKoy, Antonio C Westphalen, Daniel W Lin, Yaw A Nyame
Nature Reviews. Urology. 2026-08-01
Systematic analysis of hippo pathway signaling identifies TEAD1 as a transcriptional regulator of neuroendocrine prostate cancer.
Lisha G Brown, Ilsa M Coleman, Tony L H Chu, Erolcan Sayar, Radhika A Patel
Neoplasia. 2026-08-01
Stockholm3-Magnetic Resonance Imaging Population-Based Prostate Cancer Screening Study: Two-Year Follow-up.
Thorgerdur Palsdottir, Chiara Micoli, Martin Eklund, Henrik Grönberg, Fredrik Jäderling
Annals of Internal Medicine. 2026-07-01

Journal Articles

Re: Effects of short-term finasteride on apoptotic factors and androgen receptors in prostate cancer cells.
Lin DW, Journal of Urology
Treatment of Metastatic Prostate Cancer – How Urologists should Sequence Available Agents.
Mostaghel EA and Lin DW, AUA Update Series
Is Pre-diagnosis PSA Velocity Predictive of the Risk of Death from Prostate Cancer Following Radical Prostatectomy?
Lin DW and Lange PH, Nature Clinical Practice Urology 1: 66

Books/Book Chapters

Practical Cases in Urology.
Chapter: Current Management of Testis Cancer
Lin DW and Lange PHEditors: AJ Wein.American Urological Association, Inc
Prostatic Diseases.
Chapter: Epidemiology and Natural History of Prostate Cancer
Page 345 - 356Lin DW and Lange PHEditors: H Lepor.W.B.Saunders Co
Prostate Cancer: Principles and Practice.
Chapter: Tumor Markers in Prostate Cancer
Page 305 - 312Lin DW, Vessella RL, and Lange PHEditors: P Carroll and A D’Amico.W.B. Saunders Co

Abstracts/Posters

Prostate cancer ≤ 2 cells from the surgical margin predicts biochemical recurrence.
Izard JP, True LD, May PC, Ellis WJ, Lange PH, Lin DW, and Wright JL, Journal of Urology 187 (4 suppl): 1641A
Transurethral Needle Ablation of the Prostate for Treatment of Benign Prostatic Hyperplasia: the University of Washington Experience.
Lin DW, Ellis WJ, American Urological Association
Reverse Transcriptase-Polymerase Chain Reaction (RT-PCR) in Bone Marrow Aspirates Following Radical Prostatectomy with Extended Follow-up.
Lin DW, Ellis WJ, Arfman EW, Sohn A, Corey E, Lange PH, Vessella RL, American Urological Association

Lectures

Beyond PSA: Utility of Novel Tumor Markers in the Setting of Elevated PSA.
American Urological Association 2008 Annual Meeting, Orlando, FL
Adjuvant Chemohormonal Therapy in High Risk Prostate Cancer: a Point-Counterpoint Debate.
Northwest Urological Society Annual Meeting, Spokane, WA
Progress and Promise in Prostate Cancer Research.
VA R&D Research Colloquium, Seattle, WA

Press Mentions

What a Prostate Cancer Diagnosis like Biden’s Means for PatientsMay 18th, 2025
Prostate Cancer Is Not a Death Sentence, New Study RevealsMarch 10th, 2025
Why Men Should Be Screened for the ‘Breast Cancer Gene’August 7th, 2024

Grant Support

Stratifying Underlying Risk in the Prostate cancer Active Surveillance Study (SURPASS)UNIVERSITY OF WASHINGTON2026–2031
Stratifying Underlying Risk in the Prostate cancer Active Surveillance Study (SURPASS)UNIVERSITY OF WASHINGTON2026–2031
Stratifying Underlying Risk in the Prostate cancer Active Surveillance Study (SURPASS)UNIVERSITY OF WASHINGTON2026–2031
Prostate cancer Active Surveillance Study (PASS) Cohort: Infrastructure Support for Cancer ResearchFRED HUTCHINSON CANCER CENTER2019–2025
In Vivo Effects Of Sulforaphane Supplementation On Normal Human ProstateNational Cancer Institute2009–2011